Patents Represented by Attorney Barbara Rae-Venter Law Group, P.C. Rae-Venter
-
Patent number: 6096547Abstract: Constructs are provided for expression of physiologically active mammalian proteins in plant cells, either in culture or under cultivation. The constructs provide a promoter functional in a plant host, a structural gene coding for mammalian protein and a terminator functional in a plant host. The construct is introduced into a plant cell to become integrated into the plant genome for expression in the plant cells or plants. The plant cells may be harvested and the mammalian protein isolated in physiologically active form.Type: GrantFiled: July 31, 1998Date of Patent: August 1, 2000Assignee: Calgene, LLCInventors: Robert M. Goodman, Vic C. Knauf, Catherine M. Houck, Luca Comai
-
Patent number: 5981839Abstract: Regulatory regions from genes expressed during a particular developmental stage or in a specific tissue are identified employing cDNA screening. The resulting regulatory regions are manipulated for use with foreign sequences for introduction into plant cells to provide transformed plants having phenotypic property which can be modulated. The invention is exemplified with light, seed and fruit-specific promoters.Type: GrantFiled: March 7, 1997Date of Patent: November 9, 1999Assignee: Calgene, LLCInventors: Vic C. Knauf, Jean C. Kridl
-
Patent number: 5981502Abstract: Novel proteins of the Chicken Anemia Virus are described and compositions for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compositions containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA molecules derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which apiece of DAN is brought into a virus infectious to the host. Besides, the Invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.Type: GrantFiled: June 7, 1995Date of Patent: November 9, 1999Assignee: Leadd B.V.Inventors: Matheus Hubertus Maria Noteborn, Guus Koch
-
Patent number: 5962289Abstract: Fusion proteins or conjugates are provided containing an amino acid sequence having a substrate binding region of a polysaccharidase such as cellulase that binds to a .beta.-1,4-glycan matrix such as cellulose. The substrate binding region is essentially without polysaccharidase activity. In the fusion protein, the substrate binding region is fused or chemically linked to a polypeptide such as an enzyme, a hormone, an immunoglobulin or a protein dye. By contacting the fusion protein with a .beta.-1,4-glycan matrix, the substrate binding region binds to the matrix to immobilize the polypeptide on the matrix. The polypeptide or fusion protein can be removed from the matrix with a protease acting on a protease recognition sequence or with a solution having a low ionic strength or high pH. In the conjugate, the substrate binding region is joined such as by covalent bonding to a non-protein chemical moiety such as a dye, chromophore, fluorescor, radionuclide or enzyme co-factor.Type: GrantFiled: January 24, 1997Date of Patent: October 5, 1999Assignee: The University of British ColumbiaInventors: Douglas G. Kilburn, Robert C. Miller, Richard A.J. Warren, Neil R. Gilkes
-
Patent number: 5958424Abstract: Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies. The use of CAV-specific antibodies thus obtained.Type: GrantFiled: August 13, 1997Date of Patent: September 28, 1999Assignee: Leadd BVInventors: Mathews H.M. Noteborn, Gerden F. De Boer
-
Patent number: 5958881Abstract: A method of inducing a temporary substantial paralysis of an area of interest in a patient undergoing a medical procedure is provided. The method involves administering a therapeutically effective amount of vasoactive intestinal peptide (VIP) admixed with a pharmaceutically acceptable carrier to a patient undergoing an endoscopy or other medical procedure.Type: GrantFiled: October 24, 1997Date of Patent: September 28, 1999Inventor: Louis Y. Korman
-
Patent number: 5952002Abstract: Novel proteins of the Chicken Anemia Virus are described and compositions for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compositions containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA molecules derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which a piece of DNA is brought into a virus infectious to the host. Besides, the invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.Type: GrantFiled: August 14, 1997Date of Patent: September 14, 1999Assignee: Leadd, BVInventors: Matheus Hubertus Maria Noteborm, Guus Koch
-
Patent number: 5932476Abstract: Recombinant genetic information (DNA or RNA), comprising a Chicken Anemia Virus (CAV)-specific nucleotide sequence and the use thereof for diagnostics, vaccination or protein production are described. Recombinant CAV protein and the use thereof for diagnostics, vaccination or production of CAV-specific antibodies, and use of CAV-specific antibodies thus obtained, are also described. The cloned complete CAV DNA genome disclosed is representative of CAV in the field, worldwide. By means of PCR with primers derived from the cloned CAV genome, CAV-specific sequences corresponding with or complementary to the nucleotide sequence described can be detected. CAV harbors a specific promoter/enhancer element which regulates the CAV transcriptional activity. Based upon this, a sensitive CAV-specific PCR and a method for validating negative PCR results and for estimating the number of CAV DNA copies present in the analyzed sample have been developed.Type: GrantFiled: June 7, 1995Date of Patent: August 3, 1999Assignee: Leadd BVInventors: Mathews H. M. Noteborn, Gerden F. De Boer
-
Patent number: 5843375Abstract: The present invention provides methods and compositions for inhibiting microbial growth through the use of aromatic aldehydes or alcohols for the purpose of disinfecting contaminated environments. The methods include the step of contacting the unsterile area with an amount of a aromatic aldehyde or alcohol sufficient to control growth of pathogenic microbes. The aldehyde or alcohol can be provided in a variety of formulations.Type: GrantFiled: June 7, 1995Date of Patent: December 1, 1998Assignee: Proguard, Inc.Inventors: Ralph W. Emerson, Bradford G. Crandall, Jr.
-
Patent number: 5839224Abstract: Methods and compositions based upon natural aromatic compounds are provided, which find use as pesticides. The pesticides are formulated in a variety of ways, including dusts, sprays, shampoos and soaps, and can be bound to a solid support or provided as bait or directly impregnated into organic matter infested by or susceptible to infestation by a target pest. Pests controlled include mosquitos, lice, ants, cockroaches, lice, and ticks.Type: GrantFiled: March 25, 1996Date of Patent: November 24, 1998Assignee: Proguard, Inc.Inventors: Ralph W. Emerson, Bradford G. Crandall, Jr.
-
Patent number: 5792467Abstract: Repellent compositions which contain aromatic aldehydes such as cinnamic aldehyde, .alpha.-hexyl cinnamic aldehyde and/or coniferyl aldehyde are provided, together with methods for their use as repellents for pests including flies, cockroaches, aphids, silverleaf white flies, mosquitoes, ticks, fleas, lice, leafhoppers, thrips, two-spotted spider mites, snails, slugs, biting midges, earwigs, and moths. Also provided are stabilized .alpha.-hexylcinnamic aldehyde (HCA) compositions which reduce the evaporation rate of HCA and/or induce HCA to evaporate at a constant rate over time.Type: GrantFiled: December 24, 1996Date of Patent: August 11, 1998Assignee: Proguard, Inc.Inventors: Ralph W. Emerson, Bradford G. Crandall, Jr.
-
Patent number: 5738861Abstract: The present invention provides methods and compositions for inhibiting microbial growth through the use of flavonoid aldehydes or alcohols for the purpose of disinfecting contaminated environments. The methods include the step of contacting the unsterile area with an amount of a flavonoid aldehyde or alcohol sufficient to control growth of pathogenic microbes. The aldehyde or alcohol can be provided in a variety of formulations.Type: GrantFiled: November 22, 1995Date of Patent: April 14, 1998Assignee: Proguard, Inc.Inventors: Ralph W. Emerson, Bradford G. Crandall, Jr.